ангиотензин-(1-5) 是一种强大的内源性 ангиотензин AT 2-受体激活剂
bioRxiv : the preprint server for biology
|July 1, 2024
概括
ангиотензин-(1-5) [Ang-(1-5) ]是一种强效的,内源性激动剂的 ангиотензинAT2受体 (AT2R). 这种激活内皮氧化合成酶,促进血管扩张和降低血压.
科学领域:
- 心血管研究研究心血管研究
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 氨基酶系统 (RAS) 包含许多,受体和酶.
- 血管素片段的生物活性和受体相互作用尚未完全理解.
研究的目的:
- 为了研究血管素-(1-5) [Ang-(1-5) ]的生物活性,血管素II的一部分.
- 确定通过Ang-(1-5) 发挥其作用的特定受体.
主要方法:
- 使用DAF-FM染色,评估内皮细胞和转染细胞中氧化 (NO) 的释放.
- 在小鼠中腹腔和人类动脉中通过线筋图评估了血管扩张作用.
- 用米勒导管测量小鼠的血压.
- 在机理学研究中利用了AT2R淘汰赛小鼠和受体对抗剂.
- 确认Ang-(1-5) 与AT2R结合,并使用in silico对接确定构造.
- 通过定量基蛋白质组学映射Ang-(1-5) 信号网络.
主要成果:
- Ang-(1-5) 在特定的酸化位点激活内皮氧化合成酶 (eNOS),增加NO的释放.
- Ang-(1-5) 诱导了动脉的血管扩张,并降低了小鼠的血压,其影响取决于AT2R.
- Ang-(1-5) 显示出比已知的AT2R激动剂C21.1具有更高的功效.
- 在模拟中发现Ang-(1-5) 与AT2R的独特结合形状.
- Ang-(1-5) 调节的信号通路与内皮细胞生理学和疾病相关.
结论:
- ангиотензин-(1-5) 已被确定为强大的,内源性的 ангиотензинAT2受体 (AT2R) 激动剂.
- Ang-(1-5) 介导着与内皮功能和疾病状态相关的保护性,RAS典型的信号传递.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
700
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
700
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
606
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
606
01:25Antihypertensive Drugs: Direct Renin Inhibitors
557
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
557
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
01:31Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K